Pay in 4 interest-free payments of $6.78 Learn more
Ships within 48 hours · Estimated delivery Sep 9 - Sep 14
After 72 weeks of treatment, 62.9% of participants had less inflammation and fat accumulation in their livers
Dont push it
MaxHealth empowers you to achieve real, long-term health goals to embrace a life of maximum living 4.5 Enabling you to live life to the max Platform Simplify your health journey with our all-in-one telemedicine platform, providing effective treatments and dedicated professional support Treatments Benefit from branded subscription treatments and medications, ensuring effective healthcare is always within your reach Coaching Receive nutritional advice tailored to your unique needs, goals, and lifestyle preferences, because nobody is a one-size-fits-all solution Fitness Embrace a holistic approach to wellness with our accessible fitness programs and coaching MaxHealth'smedicine cabinet Browse our range of top-tier medications
Tirzepatide (Mounjaro), a dual GIP/GLP-1 receptor agonist approved for type 2 diabetes in the UK, has a similar adverse effect profile to other GLP-1 medications
Warnhinweise Die empfohlene Tagesdosis darf nicht berschritten werden
This may influence how the combination is formulated and recommended for use
